Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 15/20 | 0.69 |
| ▸ | CA1 | P00915 | 14/20 | 0.69 |
| ▸ | CA2 | P00918 | 14/20 | 0.69 |
| ▸ | CA12 | O43570 | 6/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.69 |
| ▸ | CA7 | P43166 | 2/20 | 0.69 |
| ▸ | ELF3 | P78545 | 1/20 | 0.58 |
| ▸ | MED23 | Q9ULK4 | 1/20 | 0.58 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.58 |
| ▸ | HTR3A | P46098 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12185010 | 0.91 | CA9 (0.70) | CA9CA1CA2CA12CA14 | |
| SCHEMBL14032096 | 0.91 | CA9 (0.72) | CA9CA1CA2CA12CA14 | |
| SCHEMBL17793595 | 0.91 | CA9 (0.72) | CA9CA1CA2CA12CA14 | |
| SCHEMBL14089616 | 0.90 | CA9 (0.73) | CA9CA1CA2CA12CA14 | |
| SCHEMBL12185092 | 0.90 | CA9 (0.73) | CA9CA1CA2CA12CA14 | |
| SCHEMBL24257626 | 0.89 | CA9 (0.70) | CA9CA1CA2CA12CA14 | |
| SCHEMBL15958213 | 0.89 | CA9 (0.70) | CA9CA1CA2CA12CA14 | |
| SCHEMBL17049667 | 0.89 | CA9 (0.74) | CA9CA1CA2CA12CA14 | |
| SCHEMBL21186772 | 0.89 | CA9 (0.65) | CA9CA1CA2CA12CA14 | |
| SCHEMBL15910186 | 0.89 | CA1 (0.68) | CA9CA1CA2CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220047725-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-02-17 | — | — | US | disclosed |
| US-11179482-B2 | Chemiluminescent probes for diagnostics and in vivo imaging | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2021-11-23 | — | — | US | disclosed |
| US-20200237932-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2020-07-30 | — | — | US | disclosed |
| US-10660974-B2 | Chemiluminescent probes for diagnostics and in vivo imaging | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2020-05-26 | — | — | US | disclosed |
| US-20190290787-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10660974-B2 | Chemiluminescent probes for diagnostics and in vivo imaging | DAXX, DCAF15, DCAF1 | CA9 568/4885CA1 1716/4885CA2 2871/4885 |
| US-20200237932-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | DAXX, DCAF15, CDY1; CDY1B | CA9 370/4885CA1 504/4885CA2 1996/4885 |
| US-20220047725-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | DAXX, DCAF15, CDY1; CDY1B | CA9 370/4885CA1 504/4885CA2 1996/4885 |
| US-11179482-B2 | Chemiluminescent probes for diagnostics and in vivo imaging | DAXX, DCAF15, CDY1; CDY1B | CA9 370/4885CA1 504/4885CA2 1996/4885 |
| US-20190290787-A1 | CHEMILUMINESCENT PROBES FOR DIAGNOSTICS AND IN VIVO IMAGING | DAXX, DCAF15, DCAF1 | CA9 568/4885CA1 1716/4885CA2 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.